1		Subarachnoid Hemorrhage Trials:
2		Cutting, Sliding, or Keeping mRS Scores and WFNS Grades
3		
4	Akshitkumar	M. Mistry, MD; ¹ Jeffrey Saver, MD; ² William Mack, MD; ³ Hooman Kamel, MD; ⁴
5	Jordan Elm,	PhD; ⁵ Jonathan Beall, PhD ⁵
6		
7	¹ Department	of Neurosurgery, University of Louisville, Louisville, KY; ² Department of Neurology
8	and Compre	hensive Stroke Center, David Geffen School of Medicine, University of California,
9	Los Angeles	, CA; ³ Department of Neurosurgery, Keck School of Medicine, University of
10	Southern Ca	lifornia, Los Angeles, CA; ⁴ Clinical and Translational Neuroscience Unit, Feil Family
11	Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New	
12	York, NY; ⁵ Department of Public Health Sciences, Medical University of South Carolina,	
13	Charleston, S	SC.
14		
15	Short title: Outcomes, Eligibility, & Sample Size in SAH Trials	
16	Total word count: 2957	
17		
18	Corresponding Author:	
19	Address:	Department of Neurological Surgery
20		University of Louisville
21		220 Abraham Flexner Way, 15th Floor
22		Louisville, KY 40202
23	Telephone:	502-588-2329
24	Fax:	502-407-3256
25	Email:	axitamm@gmail.com
26	X (Twitter) ta	igs: @UofLNeurosurg ; @HoomanKamel ; @NeurosurgryUSC ; @UCLAStroke

1

27 Abstract

28 Rigorous evidence generation with randomized controlled trials (RCTs) has lagged for 29 aneurysmal subarachnoid hemorrhage (SAH) compared to other forms of acute stroke. Besides 30 its lower incidence compared to other stroke subtypes, the presentation and outcome of SAH 31 patients also differ. This must be considered and adjusted for in designing pivotal RCTs of SAH 32 patients. Here, we show the effect of the unique expected distribution of the SAH severity at 33 presentation (World Federation of Neurological Surgeons, WFNS, grade) on the outcome most 34 used in pivotal stroke RCTs (modified Rankin Scale, mRS) and consequently on the sample 35 size. Further, we discuss the advantages and disadvantages of different options to analyze the 36 outcome and control the expected distribution of WFNS grades in addition to showing their 37 effects on the sample size. Last, we offer methods that investigators can adapt to more 38 precisely understand the effect of common mRS analysis methods and trial eligibility pertaining 39 to the WFNS grade in designing their large-scale SAH RCTs.

2

40 Purpose

The generation of rigorous evidence to inform the management of patients with aneurysmal subarachnoid hemorrhage (SAH) has lagged other types of acute strokes. The reason for this lag is multifactorial—one being that SAH has the lowest incidence of all forms of stroke. However, the paucity of SAH randomized controlled trials (RCTs) can also be self-exacerbating. Rather than adopting existing trial designs and biostatistical methods, it forces new investigators to craft these anew. Here, we provide a basic biostatistical guide for investigators to navigate two foundational dilemmas in designing large-scale SAH RCTs.

48

49 Measures of SAH Severity and Outcome

The severity of presentation universally predicts patients' functional outcomes in stroke. The ordinal World Federation of Neurological Surgeons (WFNS) scale¹ is one scale used to grade the SAH severity, increasing from 1 to 5. Although the Glasgow Outcome Scale has been used for SAH, the archetypal outcome used to measure neurological morbidity and mortality in stroke patients is the ordinal modified Rankin Scale (mRS), ranging from 0 (no neurological disability) to 6 (death). For a biostatistically-informed trial, it is critical to estimate the expected distribution of WFNS grades, mRS scores, and correlation between the two.

57

58 Expected WFNS Distribution is Skewed

The expected distribution of WFNS grades is largely skewed toward grade 1. For exemplary purposes, we retrieved a few large RCTs with broad eligibility criteria and cohort studies from different regions of the world (which should possess less selection bias common to research studies) and estimated the proportion of WFNS grade 1 to 5 (in %): 41, 22, 7, 15, 15 (Figure 1A; Supplemental Figure 1), with grade 2 being the median. For each WFNS grade, we acquired the outcome on the full mRS scale from the ULTRA² RCT (Figure 1B). We chose ULTRA because it is the most recent (2021) pivotal SAH RCT of 955 patients treated with the current standard of

3

66 care. Collectively, the skewed expected WFNS distribution and the correlation between WFNS 67 grade and mRS outcome in SAH patients may pose challenges. The effect of any intervention in 68 WFNS grade 1 patients will be diluted because 75% of them will already have a good outcome 69 (commonly accepted as mRS 0-2; Figure 1B). Conversely, unless an intervention has strong 70 therapeutic effects sufficient to improve substantial brain injury in WFNS grade 5 patients, the 71 effect size will also be diluted because 76% of them will have a bad outcome (mRS 4-6). Since 72 interventions confirmed to show a therapeutic benefit for SAH patients in RCTs are scarce,³ the 73 design of large-scale SAH RCTs must be optimized to detect a therapeutic effect considering 74 variable effects based on WFNS grade.

75

76 Outcome: Cut, Slide, or Keep mRS Scores?

Deciding how to analyze the mRS scale is a frequent dilemma. Common options are 1) fixed dichotomization, focusing on either good outcomes (mRS 0-2 vs. mRS 3-6) or bad outcomes (mRS 4-6 vs. 0-3); 2) "responder" analysis with a sliding dichotomy, prespecifying what constitutes a good outcome depending on the presenting SAH severity (for example, mRS 0-1 for WFNS grade 1, mRS 0-2 for grade 2-4, and mRS 0-4 for grade 5); and 3) "shift analysis" across all mRS scores analyzed with an ordinal regression.

83

84 We studied the impact of these options on the sample size for a two-group pivotal SAH trial 85 (80% power; two-tailed α 0.05) using the baseline (control) mRS distribution dictated by 86 expected WFNS distribution (Figure 1B-C). While fixed dichotomy at mRS 0-2 and mRS 4-6 is 87 widely accepted, there are no precedents or acceptable, validated schemes based on WFNS 88 grades for sliding dichotomy. Therefore, we generated all reasonable permutations of sliding 89 dichotomy schemes by limiting a good outcome of WFNS grade 1 to mRS ≤2 and grade 5 to 90 mRS 3-4. An mRS 0-2 for WFNS grade 5 is not only ambitious but also numerically constricts 91 the "slide" and thus greatly limits the sliding options because the fundamental principle of a

4

sliding dichotomy is cutting (or dichotomizing) the mRS scale at the same or higher mRS score for sequentially higher WFNS grades. For example, allowing dichotomization of WFNS grade 5 at mRS 2 will limit WFNS grades 1-4 to be dichotomized at mRS \leq 2 only (i.e., a "quicker" slide) as opposed to if WFNS grade 5 is dichotomized at mRS 4, then WFNS grades 1-4 can be dichotomized broadly along mRS scores \leq 4 (see examples in Supplemental Figure 2). With these rules, 99 sliding dichotomy permutations or schemes were generated. Thus, including the two commonly used fixed dichotomy schemes, we tested a total of 101 dichotomy schemes.

99

100 For exemplary purposes, we considered the common effect size of 10% absolute change in the 101 dichotomized outcomes. (For reference, Supplemental Figure 3 reviews the difference between absolute and relative effect sizes.) Using the expected mRS distribution from Figure 1C as the 102 103 control group, a fixed dichotomy at mRS 0-2 requires 14.6% more patients than at mRS 4-6 104 (754 vs. 658; see Figure 2A blue versus purple lines at 10% effect size). Sliding dichotomy 105 schemes generally lower the required sample size compared to fixed dichotomy for a 10% 106 absolute effect size. The sample size required with 49 of the 99 sliding dichotomy schemes is 107 less than that required for mRS 4-6 fixed dichotomy, and 11 sliding dichotomy schemes require 108 a sample size greater than that required for mRS 0-2 fixed dichotomy. Their sample sizes 109 depend on how quickly the "slide" occurs from WFNS grade 1 down to 5 (blue dots in 110 Supplemental Figure 4). The lowest sample size (340) is for a scheme setting a good outcome 111 for grades 1-4 at mRS 0 and grade 5 at mRS \leq 3, denoted as (0,0,0,0,3) for each sequential 112 WFNS grade, while the highest (778) is for a scheme setting a good outcome for grade 1 at 113 mRS \leq 1 and grades 2-5 at mRS \leq 4, denoted as (1,4,4,4,4). Last, if one intends to use all the 114 information across the full mRS scale rather than dichotomizing it, then the sample size can only 115 be estimated if the control mRS distribution and the expected mRS distribution for the 116 intervention are known. The sample size may be greater or lesser than the dichotomy schemes,

5

being entirely dependent on the two distributions, and the latter is often unknown. If a constant therapeutic effect is expected across all mRS scores (the practical validity of this assumption is highly arguable), then one may generate an expected mRS distribution for the intervention using a constant log odds shift (i.e., effect size; Figure 2B). With this assumption, a constant log odds shift generally yields a lower sample size than fixed dichotomies (Figure 2C).

122

123 We focused on the influence of these outcome constructions on the sample size because 124 sample size is concrete and often drives resources and cost. However, the decision should 125 ultimately be multifactorial. The advantages and disadvantages of these approaches have been discussed in this reference.⁴ For the unique expected control distribution of mRS scores for 126 127 SAH, it is critical to consider where is the greatest numerical and/or theoretical potential to 128 detect a therapeutic effect based on the biological effect of therapy (i.e., further improving the 129 outcomes of the large portion of mRS 2 patients, or decreasing mortality, the second largest 130 portion of patients-or both; Figure 1C). Last, utility-weighted mRS is an option, but it is not well-studied or measured in aSAH patients,⁵ who receive different medical and surgical 131 132 treatments compared to ischemic stroke patients.

133

134 Eligibility: Cut, Slide, or Keep WFNS Grades?

135 Eligibility criteria can influence a trial's sensitivity to detect a therapeutic effect. As discussed 136 above, interventions could be less therapeutic on either end of the WFNS grade spectrum, thus 137 including all WFNS grades may produce a diluted effect size of the intervention. While outright 138 excluding WFNS grade 1 and/or 5 patients in pivotal SAH RCTs (which make up ~55% of SAH 139 patients) is an option, we caution against it to maintain the generalizability of the intervention 140 given the lack of therapies with proven benefits in SAH patients and to not prolong the study 141 with a lower the enrollment rate. A compromising option is to limit the enrollment of patients on 142 either end of the WFNS grade spectrum. Although this reduces the enrollment rate and may

6

143 dilute the treatment effect, it maintains some level of generalizability. Given that ~40% of the 144 SAH patients are WFNS grade 1, their enrollment could be limited to a percent that is deemed 145 substantial for applicability of the results in clinical practice that is deemed to not drastically slow 146 enrollment. Similarly, WFNS grade 5 patients can be limited, for example, using a different 147 approach. Recent multicenter studies have shown that WFNS grade 5 patients can be further prognostically subclassified using the 'herniated WFNS' scale.⁶ Herniated WFNS grade 5 make 148 149 up ~30% of the WFNS grade 5 patients, and an overwhelming 88% of them have a poor 150 outcome (mRS 4-6). The primary disadvantage of limiting WFNS grade 5 patients to only non-151 herniated WFNS grade 5 is the uncaptured applicability and missed opportunity to show the 152 benefit of the intervention in this subpopulation with high mortality. We evaluated the effect on 153 the sample size of limiting WFNS grade 1 from ~40% to 0 and excluding herniated WFNS grade 154 5, comparing them to the default option of keeping all patients. We estimated the sample size of 155 a two-group pivotal trial testing a 10% absolute effect size (80% power; two-tailed α 0.05).

156

157 Counterintuitively, in most cases, limiting WFNS grade 1 and excluding herniated WFNS grade 158 5 patients each increases the sample size compared to keeping all patients (Figure 2D). Limiting WFNS grade 1 decreases the sample size (max by -56) across the spectrum down to 159 160 0% in only 6 of the total 101 fixed or sliding dichotomy schemes. The maximum increase is 126. 161 Excluding herniated WFNS grade 5 patients does not change the previously established 162 dependence of sample size of the sliding dichotomy schemes on how quickly the "slide" occurs 163 from WFNS grade 1 down to 5 (Supplemental Figure 4). The "guicker" and "slower" sliding 164 dichotomy schemes experience a greater change in sample size. The largest increase in 165 sample size (70) by excluding herniated WFNS grade 5 patients occurs in a scheme setting a 166 good outcome as mRS 0 for grades 1-4 and mRS \leq 3 for grade 5 (0,0,0,0,3), while the largest 167 decreases occur in schemes setting mRS ≤ 1 for grade 1 and mRS ≤ 4 for grades 2-5 (1,4,4,4,4;

7

168 -64) and the fixed dichotomy at mRS 0-3 vs. mRS 4-6 (-68). Excluding herniated WFNS grade 5 169 patients in 30 of the 101 dichotomy schemes decreases the sample size across the range of 170 WFNS grade 1 proportions. The combined effect of excluding both WFNS grade 1 and 171 herniated WFNS grade 5 is an increase in the sample size (max +172) in 87 schemes, including 172 the fixed dichotomies, and a decrease (max -92) in 14 schemes. Of the fixed dichotomies, mRS 173 0-2 vs. mRS 3-6 is less sensitive to any of these single or combination of these approaches 174 (min 732, max 784). Last, the sample size for a test (Wilcoxon-Mann-Whitney or proportional 175 odds regression) utilizing all the information across the full mRS scale is relatively independent 176 of the two WFNS eligibility approaches we discuss simply because the sample size is entirely 177 dependent on the control and expected distributions. The latter often is unknown. Even 178 predicting the expected distribution with a constant log odds shift in the control distribution will 179 have minimal effect on the sample size.

180

181 Overall, these results seem counterintuitive. By limiting WFNS grade 1 and 5 patients, one may 182 expect a lower sample size with a greater effect size of the intervention. However, we did not re-183 estimate the sample size with a higher expected effect size, which would decrease the sample 184 size, because often preliminary estimates of the latter are unavailable. Second, these are purely 185 mathematical results. The sample size needed to test an absolute 10% decrease (i.e., effect 186 size) with the two-sample test for proportions is greatest when the control proportion is 55% 187 (Supplemental Figure 5). Because of the skewed WFNS distribution and its dependent control 188 mRS distribution, limiting WFNS grade 1 and 5 patients results in the control proportion 189 approaching 55% in most dichotomy schemes. If the effect size of the intervention being tested 190 has not been estimated with a preliminary study limiting WFNS grade 1 and 5 patients but is 191 expected to be higher, we suggest an interim analysis that best fits the study to save resources.

192

194

195 Conclusion

196 The expected distribution of WFNS scores skewed to the lowest grade dictates the sample size 197 based on the primary analysis approach. There are advantages and disadvantages of different analysis approaches (fixed or sliding dichotomy and using the full mRS scale) and options to 198 199 modify the expected WFNS distribution in a trial. Greater sample sizes are required for fixed 200 dichotomies (especially mRS 0-2 vs. 3-6) and while most of the sliding dichotomies yield a lower 201 sample size, there is no established precedent for picking one scheme over the other. Although 202 sample size estimates are more precise when using all information across the entire mRS scale, 203 this requires that both the control and expected distributions are known. While estimating the 204 latter with a constant therapeutic effect across all mRS scores can be done and offers the 205 greatest power compared to dichotomous schemes, the practical validity of this approach is 206 arguable. Generally, limiting WFNS grade 1 enrollment and excluding justified subpopulations of WFNS grade 5 to increase the effect size of the intervention being tested will also increase the 207 208 sample size. We provide the R code (Supplemental Content) that investigators can adapt to 209 their expected WFNS and mRS distributions to navigate the two foundational dilemmas more 210 precisely in designing large-scale SAH RCTs.

211

Acknowledgments: We thank René Post, MD, PhD, Department of Neurosurgery,
Neurosurgical Centre Amsterdam, Amsterdam University Medical Centres, Amsterdam, the
Netherlands, for providing aggregated data from ULTRA.

215

216 Sources of funding: NINDS U01NS087748 (J.E. and J.B.)

217

218 Disclosures: None

9

219 References

- Report of world federation of neurological surgeons committee on a universal
 subarachnoid hemorrhage grading scale. *J Neurosurg*. 1988;68:985-986.
- Post R, Germans MR, Tjerkstra MA, Vergouwen MDI, Jellema K, Koot RW, et al. Ultra early tranexamic acid after subarachnoid haemorrhage (ultra): A randomised controlled
 trial. *Lancet.* 2021;397:112-118.
- 3. Hoh BL, Ko NU, Amin-Hanjani S, Hsiang-Yi Chou S, Cruz-Flores S, Dangayach NS, et
 al. 2023 guideline for the management of patients with aneurysmal subarachnoid
 hemorrhage: A guideline from the american heart association/american stroke
 association. *Stroke*. 2023;54:e314-e370.
- Saver JL. Optimal end points for acute stroke therapy trials: Best ways to measure
 treatment effects of drugs and devices. *Stroke*. 2011;42:2356-2362.
- Custal C, Koehn J, Borutta M, Mrochen A, Brandner S, Eyupoglu IY, et al. Beyond
 functional impairment: Redefining favorable outcome in patients with subarachnoid
 hemorrhage. *Cerebrovasc Dis.* 2021;50:729-737.
- 6. Raabe A, Beck J, Goldberg J, WJ ZG, Branca M, Marbacher S, et al. Herniation world federation of neurosurgical societies scale improves prediction of outcome in patients with poor-grade aneurysmal subarachnoid hemorrhage. *Stroke*. 2022;53:2346-2351.

10

238 Figure Legends





240 Figure 1. Expected distribution of World Federation of Neurological Surgeons (WFNS)

241 grades (A) and modified Rankin Scale (mRS) scores for subarachnoid hemorrhage

patients (B,C). Data in (A) are derived from a weighted average of 8 large studies in
Supplemental Figure 1 and (B) from the ULTRA trial.

11



245 Figure 2. Samples size calculations for a two-group pivotal subarachnoid hemorrhage 246 trial. WFNS=World Federation of Neurological Surgeons; mRS=modified Rankin Scale. Sample size estimates for (A) two examples of sliding and two fixed dichotomized outcomes using a 247 248 two-sample test of proportions and (B) shift analysis using the Wilcoxon-Mann-Whitney test and 249 control distribution in Figure 1C and (C). The sliding notation, for example, 1,4,4,4 designates 250 the dichotomizing mRS score (\leq) for each WFNS grade sequentially. (C) compares sample 251 sizes of shift analyses by equating them to the effect sizes in a dichotomous analysis of mRS. 252 (D) Sample size estimates based on WFNS grade 1 enrollment and grade 5 eligibility.

253 SUPPLEMENTAL CONTENT





254

Supplemental Figure 1. Estimation of expected World Federation of Neurological Surgeons
(WFNS) grade in SAH patients. WFNS grade distributions from selected 8 studies are depicted.
The weighted average is calculated and also plotted in manuscript Figure 1A. The references
for these studies are listed below.

259

260 References:

261 IMASH - Wong GKC, et al., IMASH Investigators. Intravenous magnesium sulphate for 262 aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-263 controlled, multicenter phase Ш trial. Stroke 2010 May;41(5):921-6. doi: 264 10.1161/STROKEAHA.109.571125; PMID:20378868

265	
266	Cohen – Cohen, et al., Dysnatremia and 6-Month Functional Outcomes in Critically III Patients
267	With Aneurysmal Subarachnoid Hemorrhage: A Prospective Cohort Study. Crit Care Explor
268	2021 Jun 8;3(6):e0445. doi: 10.1097/CCE.000000000000445; PMID: 20378868
269	
270	Tirilazad / D-SAT / SHOP - Data obtained from Jaja, et al., Development and validation of
271	outcome prediction models for aneurysmal subarachnoid haemorrhage: the SAHIT multinational
272	cohort study. BMJ 2018 Jan 18;360:j5745. doi: 10.1136/bmj.j5745. PMID: 29348138
273	
274	Hosogai – Hosogai, et al., Changes in Short-Term Outcomes After Discharge in Patients with
275	Aneurysmal Subarachnoid Hemorrhage: A Multicenter, Prospective, Observational Study. World
276	Neurosurg 2022 Aug;164:e1214-e1225; PMID: 35688375
277	
278	ULTRA – Post, et al., Ultra-early tranexamic acid after subarachnoid haemorrhage (ULTRA): a
279	randomised controlled trial. Lancet 2021 Jan 9;397(10269):112-118. doi: 10.1016/S0140-
280	6736(20)32518-6; PMID: 33357465
281	
282	Galea - Galea, et al., Predictors of Outcome in Aneurysmal Subarachnoid Hemorrhage
283	Patients: Observations From a Multicenter Data Set. Stroke 2017 Nov;48(11):2958-2963. doi:
284	10.1161/STROKEAHA.117.017777; 28974630





292 **Supplemental Figure 2.** Examples of sliding dichotomies. Showing in green and red are quick 293 and slow slides. The notation, for example, 1,1,2,3,4 designates the dichotomizing mRS score

294 (\leq) for each WFNS grade sequentially.

15

295



296

Supplemental Figure 3. Examples of overall (absolute) vs. relative shifts. For exemplary purposes, we crafted a 3-scale ordinal mRS outcome (A, B, C). The control (baseline) distribution is shown with 50% of the patients having outcome A, 30% B, and 20% C. "Back -10%" depicts the resulting distribution from the baseline by starting to decrease the proportion of patients with outcome C by 10%. "Front +10%" depicts the resulting distribution from the baseline by starting to increase the proportion of patients with outcome A by 10%. "Overall 10%" depicts the resulting distribution of a 10% absolute shift.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.28.23296257; this version posted October 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.



304

Supplemental Figure 4. Sample size estimates of 101 dichotomization schemes. The notation, for example, 11234 designates the dichotomizing mRS score (\leq) for each WFNS grade sequentially: mRS \leq 1 for grade 1, mRS \leq 1 for grade 2, mRS \leq 2 for grade 3, mRS \leq 3 for grade 4, and mRS \leq 4 for grade 5. There are two fixed dichotomy schemes: 22222, which equates to mRS \leq 2, and 33333, which equates to mRS \geq 4 (which is the same as mRS \leq 3). Red dots are sample sizes when WFNS grade 1 patient enrollment is limited to 20% from what is expected (41.5%).



Sample Size for a Two-Sample Test for Proportions

312 Supplemental Figure 5. Sample size estimates for a two-sample test for proportions.